Stock Detail
$PFE
Healthcare · 8 tracked mentions in the last 90 days across 6 creators.
Valuation and creator stance reflect the last 90 days. The mention feed below shows the latest tracked mentions across all history.
PFE leans undervalued across 3 creators and 3 classified valuation claims, with 2 direct claims carrying most of the signal.
Creator Evidence
Why creators say this
Explicit claim • strong conviction • basis: market mispricing
So when you step back and look at the big picture, Pfizer is not a short-term trade. It is a long-term compounding machine that is currently being priced as if its best days are behind it.
Explicit claim • strong conviction • basis: fair value gap
Pfizer (PFE) is a buy, presenting deep value with a dirt-cheap valuation, a high dividend yield, and strategic acquisitions in key growth areas.
Explicit claim • moderate conviction • basis: multiple relative
And number five is Fiser. This is probably the cheapest stock in the group on headline valuation.
Implied claim • weak conviction • basis: explicit term
Fizer as well with a free cash flow payout ratio of above 100%.
Mention History
Latest mentions across all history
Feed